Encoded Therapeutics
Gene therapy company developing innovative precision genetic medicines for serious neurological diseases, using cell type-selective gene regulation technology for targeted therapeutic effects.
Notes
Encoded Therapeutics is a gene therapy company headquartered in South San Francisco, California, focused on developing precision genetic medicines for serious neurological diseases. The company's platform leverages cell type-selective gene regulation to develop therapies that can precisely target specific cell populations in the nervous system.
Encoded's approach addresses a key challenge in gene therapy: achieving therapeutic effects in the right cells while minimizing effects in others. This precision is particularly important in neurological diseases where different cell types play distinct roles in disease pathology.
The company has programs targeting rare genetic epilepsies and other neurological conditions where genetic approaches could provide transformative benefits for patients with limited treatment options.
Team
- Kartik Bhavsar - CEO
- David L. Bhatt - Chief Business Officer
- Bryan Stuart, Ph.D. - Chief Scientific Officer
Additional Research Findings
- Founded in 2016
- Headquarters: South San Francisco, California
- Focus on neurological genetic diseases
- Cell type-selective gene regulation platform
- Target indications include rare genetic epilepsies (Dravet syndrome)
- Raised significant venture funding
- Investors include ARCH Venture Partners, F-Prime Capital, others
- Precision genetic medicine approach
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Illumina Ventures | San Francisco, California, USA | biotech-focused | seedseries-a+1 | 32 |